PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ETJefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMT A live audio webcast of each presentation can also be accessed via the investors se ...

Core Viewpoint - Amicus Therapeutics will host a conference call on November 4, 2025, to discuss its financial results for the quarter ended September 30, 2025 [1]. Group 1: Conference Call Details - The conference call will take place at 8:30 a.m. ET [1]. - Participants must register online to access the call by phone, receiving a dial-in number and personal PIN after registration [2]. - A live audio webcast and related presentation materials will be available on the company's corporate website [2]. Group 2: Post-Event Information - An archived webcast and accompanying slides will be accessible on the company's website shortly after the live event concludes [3]. Group 3: Company Overview - Amicus Therapeutics is a global biotechnology company focused on developing high-quality medicines for rare diseases [4]. - The company emphasizes patient dedication and aims to advance a pipeline of innovative medicines [4].

Core Viewpoint - Amicus Therapeutics is viewed as a potential investment opportunity, particularly in the context of its previous performance and the analyst's ongoing research in the healthcare sector [1]. Group 1 - The initial report on Amicus Therapeutics was published in June 2025, where it was rated as a "Buy" [1]. - The analyst emphasizes the importance of learning from both investment successes and failures, viewing investing as a continuous educational process [1]. - The analyst has focused research on various stocks for approximately five years, with a primary emphasis on healthcare stocks in recent years [1]. Group 2 - The analyst holds a beneficial long position in Amicus Therapeutics shares, indicating confidence in the company's future performance [2]. - The article reflects the analyst's personal opinions and experiences, with no external compensation influencing the views expressed [2].

Core Insights - Amicus Therapeutics (NASDAQ: FOLD) is being revisited after an initial report in June 2025, where it was rated as a "Buy" [1] - The author emphasizes the learning process in investing, viewing failures as tuition and successes as lessons learned [1] Company Overview - Amicus Therapeutics is focused on the healthcare sector, particularly in pharmaceuticals [1] - The company has been the subject of focused research for approximately five years, indicating a commitment to understanding its market position and potential [1] Investment Position - The analyst holds a beneficial long position in Amicus shares, indicating confidence in the company's future performance [2] - There is an intention to potentially buy more shares in the next 72 hours, suggesting a bullish outlook on the stock [2]

Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as a high-potential biotech stock, with recent upgrades from analysts indicating strong market confidence [1][2]. Analyst Ratings - Needham analyst Gil Blum upgraded Amicus Therapeutics to a Buy rating with a price target of $14.00 on September 18 [1]. - Morgan Stanley analyst Maxwell Skor maintained a Buy rating with a price target of $12.00 on September 17 [2]. - The consensus rating for Amicus Therapeutics is a Strong Buy, with a median price target of $8.41, suggesting an upside potential of 78.25% from current levels [2]. Company Overview - Amicus Therapeutics focuses on discovering, developing, and delivering medicines for metabolic diseases [3]. - The company’s product portfolio includes the first and only approved oral precision medicine for Fabry disease, a clinical-stage treatment for Pompe disease, and a gene therapy portfolio for rare diseases [3].

Core Viewpoint - Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Amicus Therapeutics for the fiscal year ending December 2025 is projected at $0.31 per share, remaining unchanged from the previous year [9]. - Over the past three months, analysts have increased their earnings estimates for Amicus Therapeutics by 37.5% [9]. Zacks Rating System - The Zacks rating system is based solely on a company's changing earnings picture, with a strong correlation between earnings estimate revisions and stock price movements [2][5]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10][11]. Market Implications - The upgrade to Zacks Rank 1 positions Amicus Therapeutics among the top 5% of stocks in terms of estimate revisions, suggesting potential for near-term price increases [11]. - Rising earnings estimates and the corresponding rating upgrade reflect an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [6].

Core Insights - Investor sentiment remains bullish despite tariff policies leading to higher inflation, with the Federal Reserve lowering interest rates for the first time this year amid a deteriorating labor market [1] Group 1: Stock Recommendations - Stocks such as Amicus Therapeutics, Inc. (FOLD), Micron Technology Inc. (MU), and General Dynamics Corp. (GD) are recommended for investment based on broker ratings [2] - Amicus Therapeutics is focused on developing treatments for rare metabolic diseases, with a projected earnings increase of 29.2% year-over-year for 2025 and a 7.7% upward revision in broker ratings [7] - Micron Technology, a leading provider of semiconductor memory solutions, is expected to see a 100% year-over-year earnings surge for fiscal 2026, with a 2.7% upward revision in broker ratings [8] - General Dynamics, involved in mission-critical systems and technologies, is forecasted to have an 11.7% earnings increase for 2025, with a 4.8% upward revision in broker ratings [9][10] Group 2: Investment Strategy - A screening strategy is proposed to identify potential winners, focusing on stocks with broker rating upgrades of 1% or more over the past four weeks, current prices above $5, and an average 20-day volume greater than 100,000 [5] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) have a proven record of success, especially when combined with a VGM Score of A or B, indicating strong upside potential [6]

Core Insights - Amicus Therapeutics' lead product, Galafold, is the primary revenue driver for the company, being the first oral precision medicine approved for Fabry disease treatment [1][2] - Galafold sales reached $233.1 million in the first half of 2025, reflecting an 11% year-over-year increase, with a projected CAGR of 11.7% over the next three years [2][9] - The company has secured strong patent protection for Galafold in the U.S. until 2038, following a licensing agreement with Teva Pharmaceuticals that prevents generic competition until January 2037 [3][4][9] Product Performance - Galafold has shown consistent sales growth since its launch, with label expansions and approvals in new regions contributing to its revenue increase [2][3] - The combination therapy Pombiliti + Opfolda for late-onset Pompe disease generated $46.8 million in sales during the first half of 2025, marking a 74% year-over-year increase [5] Market Dynamics - Amicus is heavily reliant on Galafold for revenue, which poses risks if regulatory challenges arise [6] - The company faces significant competition from established players in the lysosomal storage disorder market, including Sanofi and Takeda Pharmaceuticals, which market products for Fabry and Pompe diseases [7][8]

Group 1 - The article highlights three biotech stocks trading under $10.00 per share as potential investment opportunities [1] - The investing group, The Biotech Forum, offers a model portfolio consisting of 12-20 high upside biotech stocks along with live chat discussions and weekly research updates [1] - The group provides market commentary and portfolio updates every weekend, indicating a commitment to ongoing investor engagement [1]

Core Insights - Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are focused on developing treatments for rare medical conditions, aiming to establish leadership in their respective fields [1][2] Rigel Pharmaceuticals (RIGL) - Rigel's lead drug, Tavalisse, is an oral spleen tyrosine kinase inhibitor approved for chronic immune thrombocytopenia (ITP), generating $68.5 million in sales in the first half of 2025, a 44% increase year over year [3][6] - The company is also progressing with Rezlidhia, approved for relapsed/refractory acute myeloid leukemia (AML), with sales increasing 31% year over year in the first half of 2025 [4] - Rigel added Gavreto to its portfolio in 2024, contributing to revenue growth in the first half of 2025 [5] - The company raised its total revenue guidance for 2025 to $270-$280 million, up from a previous estimate of $200-$210 million, due to strong sales performance [6] - Rigel has a pipeline product, R289, in early-stage studies for myelodysplastic syndrome (MDS) and is exploring Rezlidhia's use in other cancers [7] Amicus Therapeutics (FOLD) - Amicus' lead product, Galafold, generated $233.1 million in sales in the first half of 2025, an 11% year-over-year increase, with patent protection extending to 2038 [8][9] - The company’s two-component therapy, Pombiliti + Opfolda, approved for late-onset Pompe disease, generated $46.8 million in sales in the first half of 2025, a 74% increase year over year [10] - Amicus is experiencing a shift of patients from Sanofi's Pompe disease drugs to Pombiliti and Opfolda, with expectations for increased patient starts in new markets in the second half of 2025 [11] - Despite the growth of Galafold and Pombiliti + Opfolda, FOLD remains heavily reliant on Galafold for revenue, posing a risk to the company's overall growth [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Rigel's 2025 sales and EPS indicates a year-over-year increase of approximately 57% and 415%, respectively [13] - In contrast, Amicus' 2025 sales and EPS estimates imply a year-over-year increase of around 18% and 29%, respectively, with EPS estimates for 2025 trending downward [17] - Year-to-date, RIGL shares have increased by 80.1%, while FOLD shares have decreased by 11.3%, compared to an industry return of 11.7% [19] - Amicus is valued higher than Rigel based on the price-to-sales (P/S) ratio, with FOLD trading at 4.51 times trailing sales compared to RIGL's 2.05 [20] Comparative Analysis - Rigel holds a Zacks Rank 1 (Strong Buy), indicating a more favorable investment outlook compared to Amicus, which has a Zacks Rank 3 (Hold) [24] - Rigel's strong performance and optimistic guidance for 2025, driven by Tavalisse and other products, suggest significant upside potential [25] - Amicus' reliance on Galafold and competition from established players like Sanofi present challenges for sustained growth [26] - Rigel's expanding portfolio, improving earnings estimates, and lower valuation position it as a more attractive investment compared to Amicus [27]